These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 554489)

  • 1. [Piribedil (TF 871) in the treatment of arteriopathies of the lower extremities].
    Argenteri A; Moia R; Negri L
    Ann Ital Chir; 1979; 51(2):145-55. PubMed ID: 554489
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of arteriosclerotic peripheral chronic obliterating arteriopathies (A.P.C.O.) of the lower extremities with a new pharmacologic combination].
    Bagliani A; Borri P; Parravicini R
    Minerva Cardioangiol; 1975 Nov; 23(11):701-10. PubMed ID: 1223674
    [No Abstract]   [Full Text] [Related]  

  • 3. [Piribedil in arterial diseases].
    Cristol R; Arnaud F
    Nouv Presse Med; 1974 Nov 30-Dec 14; 3(41-43):2573-4. PubMed ID: 4619431
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment with piribedil in peripheral arterial diseases].
    Gatta L; Corti G; Bernasconi S
    Minerva Med; 1976 May; 67(25):1668-70. PubMed ID: 778669
    [No Abstract]   [Full Text] [Related]  

  • 5. Action of piribedil in Parkinson's disease: I.V. test and oral treatment.
    Emile J; Chanelet J; Truelle JL; Bastard J
    Adv Neurol; 1975; 9():409-13. PubMed ID: 1096577
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapeutic acquisitions on chronic obliterating peripheral arterial diseases of the lower limbs].
    Guagliano G; Bagliani A; Borri P
    Minerva Med; 1976 May; 67(25):1648-55. PubMed ID: 778666
    [No Abstract]   [Full Text] [Related]  

  • 7. [Piribedil in the treatment of Parkinson disease (author's transl)].
    Nardini M; Sciannandrone R; Fieschi C; De Simone G
    Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
    Rondot P; Bathien N; Dumas JL
    Adv Neurol; 1975; 9():373-81. PubMed ID: 1096574
    [No Abstract]   [Full Text] [Related]  

  • 9. [Current news in the pharmacological and surgical treatment of chronic, peripheral, obliterating arterial diseases of the lower limbs].
    Argenteri A; Bagliani A; Borri P; Ugolini U
    Clin Ter; 1974 Aug; 70(3):281-91. PubMed ID: 4423739
    [No Abstract]   [Full Text] [Related]  

  • 10. [Use of buflomedil in the treatment of obliterative arteriopathies of the lower extremities. Clinical and functional study].
    Cospite M; Ferrara F; Milio G; Meli F
    Clin Ter; 1984 Apr; 109(2):127-35. PubMed ID: 6234122
    [No Abstract]   [Full Text] [Related]  

  • 11. Actions of dopaminergic agonists in parkinsonism.
    McDowell FH; Sweet R
    Adv Neurol; 1975; 9():367-71. PubMed ID: 1096573
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of an infusion of piribedil in normal subjects and in patients with peripheral obliterating arterial disease on the blood flow of the lower limbs and on blood, plasma and serum viscosity].
    Forconi S; Guerrini M; Agnusdei D; Di Perri T
    Minerva Med; 1976 May; 67(25):1671-80. PubMed ID: 934519
    [No Abstract]   [Full Text] [Related]  

  • 13. [The results of the drug therapy of the ischemic syndrome in arteriosclerosis obliterans].
    Prokhorov GG; Potapov VV; Ogneva NS; Zybina NN
    Vestn Khir Im I I Grek; 1994; 152(1-2):30-4. PubMed ID: 7701736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An assessment of the efficacy of intravenous monotherapy with the preparation solcoseryl in patients with arteriosclerosis obliterans of the vessels of the lower extremities].
    Luk'ianov IuV; Shlomin VV; Sokurenko GIu; Didenko IuP; Orlov NN; Kondrat'ev VM; Batalin IV
    Vestn Khir Im I I Grek; 2000; 159(3):81-4. PubMed ID: 10983350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ozone therapy, a new method of treating chronic obliterating arteriopathies].
    Ionescu G; Pitea P; Blaj A
    Rev Chir Oncol Radiol O R L Oftalmol Stomatol Chir; 1985; 34(3):207-13. PubMed ID: 2931752
    [No Abstract]   [Full Text] [Related]  

  • 16. [Value of piribedil in the treatment of degenerative retinal vasculopathies].
    Perdriel G; Chevaleraud JP; Decroix G
    Bull Soc Ophtalmol Fr; 1974 Apr; 74(4):445-8. PubMed ID: 4219755
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical trials of a vasoactive drug in arteriopathies of the limbs].
    Courbier R; Jausseran JM; Reggi M
    Sem Hop Ther; 1977 Jan; 53(1):47-51. PubMed ID: 854750
    [No Abstract]   [Full Text] [Related]  

  • 18. [A trial of the use of Vasaprostan in patients with arteriosclerosis obliterans of the lower extremities].
    Lebedev LV; Dobrynin EV; Luk'ianov IuV; Ignat'ev EI; Afonin DN
    Vestn Khir Im I I Grek; 1993; 150(5-6):151-3. PubMed ID: 8091568
    [No Abstract]   [Full Text] [Related]  

  • 19. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK; Sonninen V; Marttila R
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Late results of the pyridinolcarbamate treatment of thrombotic obliterating arterial diseases of the extremities].
    Fisanovich TI; Tolstova LG
    Khirurgiia (Mosk); 1979 Sep; (9):76-80. PubMed ID: 502312
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.